<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0912211450
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2014
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ADVATE 1000 IU 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HUMAN COAGULATION FACTOR VIII
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2504.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA MANUFACTURING AUSTRIA AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA MANUFACTURING AUSTRIA AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Takeda Manufacturing Austria AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ADVATE contains the active substance octocog alfa, human<br />coagulation factor VIII produced by recombinant DNA<br />technology. Factor VIII is necessary for the blood to form clots<br />and stop bleedings. In patients with haemophilia A (inborn<br />lack of factor VIII), it is missing or not working properly.<br />ADVATE is used for the treatment and prevention of bleeding<br />in patients of all age groups with haemophilia A (an inherited<br />bleeding disorder caused by lack of factor VIII).<br />ADVATE is prepared without the addition of any human‑ or<br />animal‑derived protein in the entire manufacturing process.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash;&ndash; if you are allergic to octocog alfa or any of the other<br />ingredients of this medicine (listed in section 6)<br />&ndash;&ndash; if you are allergic to mouse or hamster proteins<br />If you are unsure about this, ask your doctor.<br />Warnings and precautions<br />Talk to your doctor before using ADVATE. You should tell your<br />doctor if you have been previously treated with Factor VIII<br />products, especially if you developed inhibitors, since there<br />might be a higher risk that it happens again. Inhibitors are<br />blocking antibodies against factor VIII that reduce the efficacy<br />of ADVATE to prevent or control bleeding. Development<br />of inhibitors is a known complication in the treatment of<br />haemophilia A. If your bleeding is not controlled with ADVATE,<br />tell your doctor immediately.<br />There is a rare risk that you may experience an anaphylactic<br />reaction (a severe, sudden allergic reaction) to ADVATE.<br />You should be aware of the early signs of allergic reactions<br />such as rash, hives, wheals, generalised itching, swelling of<br />lips and tongue, difficulty in breathing, wheezing, tightness<br />in the chest, general feeling of being unwell, and dizziness.<br />These symptoms can constitute an early symptom of an<br />anaphylactic shock, manifestations of which may additionally<br />include extreme dizziness, loss of consciousness, and extreme<br />difficulty in breathing.<br />If any of these symptoms occur, stop the injection<br />immediately and contact your doctor. Severe symptoms,<br />including difficulty in breathing and (near) fainting, require<br />prompt emergency treatment.<br />Patients developing Factor VIII inhibitors<br />If your plasma Factor VIII fails to reach expected levels with<br />ADVATE, or if bleeding is not adequately controlled, it could<br />be due to the development of Factor VIII inhibitors. This will<br />be checked by your doctor. You might need a higher dose<br />of ADVATE or even a different product to control bleedings.<br />Do not increase the total dose of ADVATE to control your<br />bleeding without consulting your doctor.<br />Children and adolescents<br />The listed warnings and precautions apply to both adults and<br />children (from 0 to 18 years of age).<br />Other medicines and ADVATE<br />Tell your doctor if you are using, have recently used or might<br />use any other medicines.<br />Pregnancy and breast‑feeding<br />If you are pregnant or breast-feeding, think you may be<br />pregnant or are planning to have a baby, ask your doctor for<br />advice before using this medicine.<br />Driving and using machines<br />ADVATE has no influence on your ability to drive or to use<br />machines.<br />ADVATE contains sodium<br />This medicine contains 0.45 mmol sodium (10 mg) per vial.<br />To be taken into consideration by patients on a controlled<br />sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with ADVATE will be started by a doctor who is<br />experienced in the care of patients with haemophilia A.<br />Your doctor will calculate your dose of ADVATE (in<br />international units or IU) depending on your condition and<br />body weight, and on whether it is used for prevention or<br />treatment of bleeding. The frequency of administration will<br />depend on how well ADVATE is working for you. Usually, the<br />replacement therapy with ADVATE is a life‑long treatment.<br />Always use this medicine exactly as your doctor has told you.<br />Check with your doctor if you are not sure.<br />Prevention of bleeding<br />The usual dose of octocog alfa is 20 to 40 IU per kg body<br />weight, administered every 2 to 3 days. However, in some<br />cases, especially in younger patients, more frequent injections<br />or higher doses may be necessary.<br />Treatment of bleeding<br />The dose of octocog alfa is calculated depending on your<br />body weight and the factor VIII levels to be achieved. The<br />target factor VIII levels will depend on the severity and<br />location of the bleeding.<br />Dose (IU) = body weight (kg) x desired Factor VIII rise<br />(% of normal) x 0.5<br />If you have the impression that the effect of ADVATE is<br />insufficient, talk to your doctor.<br />Your doctor will perform appropriate laboratory tests to<br />make sure that you have adequate Factor VIII levels. This is<br />particularly important if you are having major surgery.<br />Use in children and adolescents (from 0 to 18 years of age)<br />For the treatment of bleeding the dosing in children does<br />not differ from adult patients. For the prevention of bleeding<br />in children under the age of 6, doses of 20 to 50 IU per kg<br />body weight 3 to 4 times weekly are recommended. The<br />administration of ADVATE in children (intravenously) does<br />not differ from the administration in adults. A central venous<br />access device (CVAD) may become necessary to allow<br />frequent infusions of factor VIII products.<br />How ADVATE is given<br />ADVATE is usually injected into a vein (intravenously) by your<br />doctor or nurse. You or someone else might also administer<br />ADVATE as an injection, but only after receiving adequate<br />training. Detailed instructions for self‑administration are given<br />at the end of this package leaflet.<br />If you use more ADVATE than you should<br />Always take ADVATE exactly as your doctor has told you. You<br />should check with your doctor if you are not sure. If you inject<br />more ADVATE than recommended, tell your doctor as soon as<br />possible.<br />If you forget to use ADVATE<br />Do not inject a double dose to make up for a forgotten dose.<br />Proceed with the next injection as scheduled and continue as<br />advised by your doctor.<br />If you stop using ADVATE<br />Do not stop using ADVATE without consulting your doctor.<br />If you have any further questions on the use of this medicine,<br />ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects,<br />although not everybody gets them.<br />If severe, sudden allergic reactions (anaphylactic) occur, the<br />injection must be stopped immediately. You must contact<br />your doctor immediately if you have any of the following<br />early symptoms of allergic reactions:<br />&ndash;&ndash; rash, hives, wheals, generalised itching,<br />&ndash;&ndash; swelling of lips and tongue,<br />&ndash;&ndash; difficulty in breathing, wheezing, tightness in the chest,<br />&ndash;&ndash; general feeling of being unwell,<br />&ndash;&ndash; dizziness and loss of consciousness.<br />Severe symptoms, including difficulty in breathing and<br />(nearly) fainting, require prompt emergency treatment.<br />Common side effects (may affect up to 1 in 10 people)<br />Factor VIII inhibitors, headache and fever.<br />Uncommon side effects (may affect up to 1 in 100 people)<br />dizziness, flu, fainting, abnormal heartbeat, red itchy bumps<br />on the skin, chest discomfort, injection site bruise, injection<br />site reaction, itching, increased sweating, unusual taste in the<br />mouth, hot flushes, migraines, memory impairment, chills,<br />diarrhoea, nausea, vomiting, shortness of breath, sore throat,<br />infection of the lymphatic vessels, whitening of skin, eye<br />inflammation, rashes, excessive sweating, foot and leg swelling,<br />reduced percentage of red blood cells, increase in a type of<br />white blood cells (monocytes), and pain in the upper abdomen<br />or lower chest.<br />Related to surgery<br />catheter‑related infection, decreased red cell blood count,<br />swelling of limbs and joints, prolonged bleeding after drain<br />removal, decreased Factor VIII level and post‑operative bruise.<br />Related to central venous access devices (CVAD)<br />catheter‑related infection, systemic infection and local blood<br />clot at the catheter site.<br />Side effects with unknown frequency (frequency cannot be<br />estimated from the available data)<br />potentially life‑threatening reactions (anaphylaxis) and<br />other allergic reactions (hypersensitivity), general disorders<br />(tiredness, lack of energy).<br />Additional side effects in children<br />Other than the development of inhibitors in previously<br />untreated paediatric patients (PUPs), and catheter‑related<br />complications, no age‑specific differences in side effects were<br />noted in the clinical studies.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor. This includes<br />any possible side effects not listed in this leaflet. You can also<br />report side effects directly via following national reporting<br />system. By reporting side effects you can help provide more<br />information on the safety of this medicine:<br />To report any side effect(s):<br />&middot;&middot; Saudi Arabia:<br />Please report adverse drug events to:<br />&ndash;&ndash; The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa<br />&middot;&middot; Other GCC States:<br />&ndash;&ndash; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date, which is stated<br />on the label after EXP. The expiry date refers to the last day of<br />that month.<br />Store in a refrigerator (2 &deg;C &ndash; 8 &deg;C).<br />Do not freeze.<br />During the shelf life the powder vial may be kept at<br />room temperature (up to 25 &deg;C) for a single period not<br />exceeding 6 months. In this case, this medicine expires at the<br />end of this 6 month period or the expiration date printed on<br />the product vial, whichever is earlier. Please record the end of<br />the 6 months storage at room temperature on the product<br />carton. The product may not be returned to refrigerated<br />storage after storage at room temperature.<br />Keep the vial in the outer carton in order to protect<br />from light.<br />This product is for single use only. Discard any unused solution<br />appropriately.<br />Use the product immediately once the powder is completely<br />dissolved.<br />Do not refrigerate the solution after preparation.<br />Do not throw away any medicines via waste water or<br />household waste. Ask your pharmacist how to throw away<br />medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ndash;&ndash; The active substance is octocog alfa (human coagulation<br />Factor VIII produced by recombinant DNA technology).<br />Each powder vial contains 250 IU octocog alfa.<br />&ndash;&ndash; The other ingredients are mannitol, sodium chloride,<br />histidine, trehalose, calcium chloride, trometamol,<br />polysorbate 80, and glutathione (reduced).<br />Solvent vial: 5 ml sterilised water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ADVATE is a white to off‑white friable powder. After
reconstitution, the solution is clear, colourless and free from
foreign particles.
Each pack also contains a device for reconstitution
(BAXJECT II).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Takeda Manufacturing Austria AG<br />Industriestrasse 67<br />A‑1221 Vienna<br />Manufacturers<br />Baxter AG<br />Industriestrasse 67<br />A‑1221 Vienna<br />Baxalta Manufacturing Sarl<br />Neuch&acirc;tel<br />Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ADVATE على مادة أوكتوكوغ ألفا، وهي عامل التخثر البشري الثامن من إنتاج تقنية الحمض النووي المأشوب. العامل&nbsp;<br />الثامن ضروري ليكون الدم تجلطات ويتوقف عن النزف. لدى المرضى المصابين بالهيموفيليا أ )نقص العامل الثامن منذ الولادة(<br />يستخدم ADVATE &nbsp;ي علاج النزيف والوقاية منه لدى المرضى من كل الفئات العمرية المصابين بالهيموفيليا أ )اضطراب &nbsp;<br />وراثي في النزف ناتج عن نقص العامل الثامن(يكون مفقودًا أو لا يعمل بالشكل الصحيح.<br />يتم تجهيز ADVATE بدون إضافة أي بروتين مشتق من الإنسان أو الحيوان في كل عملية التصنيع.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ADVATE لا تستخدم<br />) - إذا كنت مصابًا بالحساسية تجاه أوكتوكوغ ألفا أو أي مكون آخر من مكونات هذا الدواء )والمدرجة في القسم 6<br />- إذا كنت مصابًا بالحساسية لبروتينات الفئران أو الجرذان،<br />وإذا لم تكن متأكدًا من هذا، فاسأل طبيبك.<br />تحذيرات واحتياطات<br />ينبغي أن تبلغ طبيبك إذا كنت قد تلقيت علاجًا في السابق بمنتجات العامل الثامن، وخاصة .ADVATE استشر طبيبك قبل استخدام<br />إذا تطورت لديك كابتات، بما أنه قد يكون هناك خطر أكبر من أن يحدث هذا مرة أخرى. الكابتات تعيق الأجسام المضادة للعامل<br />في الوقاية من النزف أو التحكم فيه. تكوين الكابتات من المضاعفات المعروفة في علاج ADVATE الثامن مما يقلل من فعالية<br />فأبلغ طبيبك فورًا. ،ADVATE الهيموفيليا أ. إذا كان نزفك لا يمكن السيطرة عليه باستخدام<br />5<br />3<br />ينبغي أن تنتبه للعلامات .ADVATE هناك خطر نادر من أنك قد تتعرض لتفاعل مفرط الحساسية )تفاعل حساسية حاد مفاجئ( تجاه<br />المبكرة لتفاعلات الحساسية مثل الشحوب والطفح الجلدي والبثور والشعور العام بالحكة وتورم الشفتين واللسان والصعوبة في التنفس<br />والصفير عند التنفس وضيق الصدر والإحساس العام بالتوعك والإعياء. يمكن أن تمثل هذه الأعراض عَرَضًا مبكرًا لصدمة حساسية<br />مفرطة، بالإضافة إلى أنها قد تظهر على شكل أعراض تشمل الغثيان الشديد وفقدان الوعي والصعوبة الشديدة في التنفس.<br />إذا حدثت أي من هذه الأعراض، فتوقف عن الحقن فورًا وتواصل مع طبيبك. تتطلب الأعراض الحادة، بما في ذلك صعوبة التنفس<br />والإغماء )الوشيك(، علاجًا فوريًا في الطوارئ.<br />المرضى الذين تظهر لديهم كابتات العامل الثامن<br />أو إذا لم يتم التحكم في النزيف ،ADVATE إذا لم يصل العامل الثامن في البلازما لديك إلى المستويات المتوقعة باستخدام<br />بالشكل الكافي، يمكن أن يعود هذا إلى تطور معيقات العامل الثامن. سيتحقق طبيبك من هذا. قد تحتاج إلى جرعة أعلى من<br />لتتحكم في نزيفك بدون ADVATE أو إلى منتج مختلف للتحكم في النزف. لا ترفع الجرعة الإجمالية من ADVATE<br />استشارة طبيبك.<br />الأطفال والمراهقون<br />تسري التحذيرات والاحتياطات المدرجة على كل من البالغين والأطفال )من الولادة وحتى عمر 11 عامًا(.<br />ADVATE استخدام الأدوية الأخرى مع<br />أخبر طبيبك إذا كنت تستخدم أي أدوية أخرى أو استخدمتها مؤخرًا أو قد تستخدمها.<br />الحمل والرضاعة الطبيعية<br />إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملاً أو تخططين للحمل، فاستشيري طبيبكِ أو<br />الصيدلاني قبل استخدام هذا الدواء.<br />القيادة واستخدام الآلات<br />على قدرتك على القيادة أو استخدام الآلات. ADVATE لا يؤثر<br />على الصوديوم ADVATE يحتوي<br />يحتوي هذا الدواء على 5.45 مليمول ) 15 ملجم( من الصوديوم في القارورة. يجب على المرضى الذين يتبعون نظامًا غذائيًا محدد<br />الصوديوم وضع هذا الأمر في الحسبان.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سيبدأ العلاج باستخدام ADVATE على يد طبيب خبير في رعاية المصابين بالهيموفيليا أ.<br />سيحسب طبيبك جرعتك من ADVATE (بالوحدات الدولية أو IU) على حسب حالتك ووزن جسمك وما إذا كان يُستخدم للوقاية من النزيف أو لعلاجه. سيعتمد تكرار الاستخدام على مدى كفاءة عمل ADVATE وفي العادة يستمر العلاج البديل من ADVATE &nbsp;طوال الحياة. احرص دومًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك. استشر طبيبك إذا لم تكن متأكدًا.<br />الوقاية من النزيف<br />تتراوح الجرعة المعتادة من أوكتوكوغ ألفا بين 25 و 45 وحدة دولية لكل كجم من وزن الجسم، ويتم حقنها كل فترة تتراوح بين<br />يومين و 3 أيام. إلا أنه في بعض الحالات، وخاصة مع المرضى الأصغر في السن، قد يكون من الضروري استخدام مرات حقن<br />أكثر أو جرعات أعلى.<br />علاج النزيف<br />يتم حساب جرعة أوكتوكوغ ألفا على حسب وزن جسمك ومستويات العامل الثامن المطلوب تحقيقها. ستعتمد المستويات المستهدفة<br />من العامل الثامن على حدة النزيف وموقعه.<br />الارتفاع المرغوب فيها للعامل الثامن )بنسبة مئوية من x ) الجرعة )بالوحدة الدولية( = وزن الجسم )بالكيلوجرام<br />x المستوى العادي( 0.5<br />غير كافٍ، فتحدث مع طبيبك. ADVATE إذا كان لديك انطباع أن أثر<br />سيقوم طبيبك بالاختبارات المعملية الملائمة للتأكد من أن لديك مستويات كافية من العامل الثامن. وهذا له أهمية خاصة إذا كنت<br />ستخضع لجراحة كبيرة.<br />الاستخدام مع الأطفال والمراهقين )من الولادة وحتى سن 11 عامًا(<br />لعلاج النزيف، لا تختلف الجرعة لدى الأطفال عن المرضى البالغين. للوقاية من النزيف لدى الأطفال الأقل من 6 سنوات،<br />يوصى بجرعات تتراوح بين 25 و 55 وحدة دولية لكل كجم من وزن الجسم ما بين 3<br />للأطفال )وريديًا( عن الحقن للبالغين. قد يصبح جهاز الوصول الوريدي ADVATE و 4 مرات في الأسبوع. لا يختلف حقن<br />ضروريًا للسماح بجرعات حقن مستمرة لمنتجات العامل الثامن. )CVAD( المركزي<br />ADVATE كيف يتم إعطاء<br />كحقن، لكن ADVATE في العادة في وريد )وريديًا(. قد تتناول أنت أو شخص آخر أيضًا ADVATE يحقن الطبيب أو الممرضة<br />بعد الحصول على تدريب كافٍ فقط. يتم تقديم تعليمات تفصيلية للحقن الذاتي في نهاية نشرة هذه العبوة.<br />ADVATE في حالة استخدام جرعة أكبر مما ينبغي من<br />تمامًا كما أخبرك طبيبك. يجب استشارة طبيبك إذا لم تكن متأكدًا. في حال حقنك جرعة ADVATE احرص دومًا على استخدام<br />أكبر من الموصى بها، أبلغ طبيبك في أسرع وقت ممكن. ADVATE<br />ADVATE إذا نسيت تناول<br />لا تحقن جرعة مزدوجة لتعويض الجرعة المنسية. واصل تناول الجرعة التالية حسب المخطط وواصل كما ينصح طبيبك.<br />ADVATE إذا توقفت عن تناول<br />دون استشارة طبيبك. ADVATE لا تتوقف عن استخدام<br />إذا كانت لديك أي أسئلة إضافية عن استخدام هذا الدواء، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>يمكن أن يتسبب هذا الدواء مثل جميع الأدوية في حدوث آثار جانبية، على الرغم من عدم تعرض جميع المرضى لها.<br />إذا حدثت تفاعلات حساسية حادة مفاجئة )فرط حساسية(، يجب إيقاف الحقن فورًا. يجب عليك التواصل مع طبيبك فورًا إذا<br />كانت لديك أي من الأعراض المبكرة التالية لتفاعلات الحساسية:<br />- شحوب، وطفح جلدي، وبثور، وشعور عام بالحكة،<br />- وتورّم في الشفتين واللسان،<br />- وصعوبة في التنفس، وصفير عند التنفس، وضيق في الصدر،<br />- وشعور عام بالتوعك،<br />- وإعياء وفقدان للوعي.<br />تتطلب الأعراض الحادة، بما في ذلك الصعوبة في التنفس والإغماء )الوشيك( علاجًا فوريًا في الطوارئ.<br />الأعراض الجانبية الشائعة )قد تؤثر على عدد يصل إلى 1 في كل 15 أشخاص(<br />كابتات العامل الثامن والصداع والحمى.<br />الأعراض الجانبية غير الشائعة )يمكن أن يتأثر بها ما يصل إلى 1 من كل 155 شخص(<br />الإعياء والإنفلونزا والإغماء وضربات القلب غير المنتظمة وكدمات حمراء مثيرة للحكة على البشرة وضيق في الصدر والرضوض<br />في موضع الحقن والتفاعل في موضع الحقن والحكة وزيادة التعرق والمذاق الغريب في الفم والاحمرار مع السخونة والشقيقة وإعاقة<br />الذاكرة والقشعريرة والإسهال والغثيان والتقيوء وقصر النفس وألم الحلق وعدوى الأوعية اللمفاوية وابيضاض البشرة والتهاب العين<br />والطفح الجلدي والتعرق الزائد وتورم القدم<br />5<br />5<br />والساق وانخفاض النسبة المئوية لكرات الدم الحمراء وزيادة نوع من كرات الدم البيضاء )أحادية النواة( وألم أعلى البطن<br />أو أسفل الصدر.<br />مرتبطة بالجراحة<br />العدوى المرتبطة بالقسطرة وانخفاض عدد كرات الدم الحمراء وتورم الأطراف والمفاصل والنزيف لمدة طويلة بعد إزالة<br />المنزح وانخفاض مستوى العامل الثامن ورضوض ما بعد العملية.<br />)CVAD( مرتبطة بأجهزة الوصول الوريدي المركزية<br />العدوى المرتبطة بالقسطرة والعدوى الجهازية وتخثر الدم الموضعي في موقع القسطرة.<br />الآثار الجانبية ذات التكرار غير المعروف )لا يمكن تقدير التكرار من البيانات المتاحة( وقد تكون تفاعلات تهدد الحياة<br />)الحساسية للبروتينات( وتفاعلات الحساسية الأخرى )الحساسية المفرطة( والاضطرابات العامة )الإحساس بالتعب وفقدان<br />الطاقة(.<br />الآثار الجانبية الإضافية لدى الأطفال<br />والمضاعفات المرتبطة بالقسطرة، لا توجد )PUP( بخلاف ظهور الكابتات لدى المرضى الأطفال الذين لم يتم علاجهم سابقًا<br />اختلافات مرتبطة بالعمر في الآثار الجانبية تمت ملاحظتها في الدراسات العيادية.<br />الإبلاغ عن الآثار الجانبية<br />إذا أُصبت بأي آثار جانبية، فتحدث مع طبيبك. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ<br />عن الآثار الجانبية مباشرة عن طريق نظام الإبلاغ الوطني المذكور أدناه. بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير<br />المزيد من المعلومات حول سلامة هذا الدواء.<br />المملكة العربية السعودية: <br />(NPC( -- المركز الوطني للتيقظ والسلامة الدوائية<br />+966-11-205 فاكس: 7662 <br />- 966 +، الرقم الداخلي: 2312 -11- اتصل بالمركز الوطني للتيقظ والسلامة الدوائية على رقم الاتصال الهاتفي 2038222 <br />.2345-2334-2354-2353-2356<br />الهاتف المجاني: 1552445555 <br />npc.drug@sfda.gov.sa : البريد الإلكتروني <br />www.sfda.gov.sa/npc : الموقع الإلكتروني&nbsp;<br />دول مجلس التعاون الخليجي الأخرى:&nbsp;<br />- يرجى الاتصال بالسلطة المختصة ذات الصلة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدًا عن متناول الأطفال وأعينهم.<br />يشير تاريخ انتهاء الصلاحية إلى آخر يوم .EXP لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الملصق بعد كلمة<br />من الشهر المذكور.<br />يخزّن في الثلاجة ) 2 درجة مئوية &ndash; 1 درجة مئوية(.<br />لا تقم بتجميد المنتج.<br />خلال فترة القابلية للتخزين، يمكن الاحتفاظ بقارورة المسحوق في درجة حرارة الغرفة )حتى 25 درجة مئوية( لفترة منفردة لا<br />تتجاوز 6 أشهر. في هذه الحالة، تنتهي صلاحية هذا الدواء في نهاية هذه الفترة التي تبلغ 6 أشهر أو تاريخ انتهاء الصلاحية المطبوع على قارورة المنتج، أيهما يأتي أولاً. يرجى تسجيل نهاية فترة التخزين البالغة 6 أشهر في درجة<br />حرارة الغرفة على عبوة المنتج. لا يمكن إعادة المنتج إلى التخزين المبرد بعد التخزين في درجة حرارة الغرفة.<br />احفظ القنينة في العبوة الكرتون الخارجية لحمايتها من الضوء.<br />هذا المنتج للاستخدام لمرة واحدة فقط. تخلص من أي محلول غير مستخدم بالشكل الملائم. استخدم<br />المنتج فورًا بمجرد ذوبان المسحوق بالكامل.<br />لا تبرد المحلول بعد تجهيزه.<br />لا تتخلص من أي أدوية عبر مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلاني الذي تتعامل معه عن طريقة التخلص<br />من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما الذي يحتوي عليه ADVATE<br />- المادة النشطة هي أوكتوكوغ ألفا )عامل التخثر البشري الثامن من إنتاج تقنية الحمض النووي المأشوب(. تحتوي كل قارورة<br />مسحوق على ما يقرب من 255 أو 555 أو 1555 أو 1555 أو 2555 أو 3555 وحدة دولية من أوكتوكوغ ألفا.<br />- المكونات الأخرى هي مانيتول وكلوريد الصوديوم وهيستيدين وتريهالوز وكلوريد الكالسيوم وتروميتامول<br />وبوليسوربيت 15 وغلوتاثيون )مخفف(.<br />قارورة المذيب: 5 مل من المياه المعقمة للحقن<br />شكل ADVATE ومحتويات العبوة<br />ADVATE عبارة عن مسحوق سريع الذوبان يتراوح بين اللون الأبيض والأبيض الداكن. بعد تجهيز المحلول، يصبح صافيًا<br />وعديم اللون وخاليًا من الجسيمات الغريبة.<br />كما تحتوي كل عبوة على جهاز للتجهيز ) BAXJECT II</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>-----</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>Takeda Manufacturing Austria AG<br />Industriestrasse 67<br />1221<br />Austria<br />Manufacturers<br />Baxter AG<br />Lange Allee 24<br />Vienna 1225<br />النمسا<br />]و[<br />Baxalta BioScience Manufacturing S&agrave;rl<br />Route de Pierre-&agrave;-Bot 111<br />CH-2000 Neuch&acirc;tel<br />سويسرا<br />Baxalta Belgium Manufacturing SA<br />Boulevard Ren&eacute; Branquart 80<br />B-7860 Lessines<br />بلجيكا<br />Baxter SA<br />Boulevard Ren&eacute; Branquart 80<br />ليسينيه B-7860<br />بلجيكا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت المراجعة الأخيرة لهذه النشرة في 25 أكتوبر 2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ADVATE 250و500 and 1000 IU powder and solvent for solution for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains nominally 250, 500 and 1000IU human coagulation factor VIII (rDNA), octocog alfa. ADVATE
contains approximately 50,100 and 200 IU per ml of human coagulation factor VIII (rDNA), octocog alfa after reconstitution.
The potency (International Units) is determined using the European Pharmacopoeia chromogenic
assay. The specific activity of ADVATE is approximately 4,000-10,000 IU/mg protein.
Octocog alfa (human coagulation factor VIII (rDNA)) is a purified protein that has 2332 amino acids.
It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. Prepared
without the addition of any (exogenous) human- or animal-derived protein in the cell culture process,
purification or final formulation.
Excipients with known effect:
0.45 mmol sodium (10 mg) per vial.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection.
Powder: White to off-white friable powder.
Solvent: Clear and colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII<br />deficiency). ADVATE is indicated in all age groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated under the supervision of a physician experienced in the treatment of<br />haemophilia and with resuscitation support immediately available in case of anaphylaxis.<br />Posology<br />The dose and duration of the substitution therapy depend on the severity of the factor VIII deficiency,<br />on the location and extent of the bleeding and on the patient&rsquo;s clinical condition.<br />The number of units of factor VIII is expressed in International Units (IU), which are related to the<br />WHO standard for factor VIII products. Factor VIII activity in plasma is expressed either as a<br />percentage (relative to normal human plasma) or in IUs (relative to the international standard for<br />factor VIII in plasma).<br />One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one ml<br />of normal human plasma.<br />3<br />On demand treatment<br />The calculation of the required dose of factor VIII is based on the empirical finding that 1 IU factor<br />VIII per kg body weight raises the plasma factor VIII activity by 2 IU/dl. The required dose is<br />determined using the following formula:<br />Required units (IU) = body weight (kg) x desired factor VIII rise (%) x 0.5<br />In case of the following haemorrhagic events, the factor VIII activity should not fall below the given<br />plasma activity level (in % of normal or IU/dl) in the corresponding period. The following table 1 can<br />be used to guide dosing in bleeding episodes and surgery:<br />Table 1 Guide for dosing in bleeding episodes and surgery<br />Degree of haemorrhage/type<br />of surgical procedure<br />Factor VIII level<br />required (% or IU/dl)<br />Frequency of doses (hours)/duration<br />of therapy (days)<br />Haemorrhage<br />Early haemarthrosis, muscle<br />bleeding or oral bleeding.<br />More extensive haemarthrosis,<br />muscle bleeding or haematoma.<br />Life threatening haemorrhages.<br />20 &ndash; 40<br />30 &ndash; 60<br />60 &ndash; 100<br />Repeat injections every 12 to 24 hours<br />(8 to 24 hours for patients under the<br />age of 6) for at least 1 day, until the<br />bleeding episode, as indicated by pain,<br />is resolved or healing is achieved.<br />Repeat injections every 12 to 24 hours<br />(8 to 24 hours for patients under the<br />age of 6) for 3 &ndash; 4 days or more until<br />pain and acute disability are resolved.<br />Repeat injections every 8 to 24 hours<br />(6 to 12 hours for patients under the<br />age of 6) until threat is resolved.<br />Surgery<br />Minor<br />Including tooth extraction.<br />Major<br />30 &ndash; 60<br />80 &ndash; 100<br />(pre- and postoperative)<br />Every 24 hours (12 to 24 hours for<br />patients under the age of 6), at<br />least 1 day, until healing is achieved.<br />Repeat injections every 8 to 24 hours<br />(6 to 24 hours for patients under the<br />age of 6) until adequate wound<br />healing, then continue therapy for at<br />least another 7 days to maintain a<br />factor VIII activity of 30% to 60%<br />(IU/dl).<br />The dose and frequency of administration should be adapted to the clinical response in the individual<br />case. Under certain circumstances (e.g. presence of a low-titre inhibitor), doses larger than those<br />calculated using the formula may be necessary.<br />During the course of treatment, appropriate determination of plasma factor VIII levels is advised to<br />guide the dose to be administered and the frequency of repeated injections. In the case of major<br />surgical interventions in particular, precise monitoring of the substitution therapy by means of plasma<br />factor VIII activity assay is indispensable. Individual patients may vary in their response to factor<br />VIII, achieving different levels of in vivo recovery and demonstrating different half-lives.<br />Prophylaxis<br />For long-term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses<br />are 20 to 40 IU of factor VIII per kg body weight at intervals of 2 to 3 days.<br />4<br />Paediatric population<br />For on demand treatment dosing in paediatric patients (0 to 18 years of age) does not differ from<br />adult patients. In patients under the age of 6, doses of 20 to 50 IU of factor VIII per kg body weight<br />3 to 4 times weekly are recommended for prophylactic therapy.<br />Method of administration<br />ADVATE should be administered via the intravenous route. In case of administration by a non health<br />care professional appropriate training is needed.<br />The rate of administration should be determined to ensure the comfort of the patient up to a maximum<br />of 10 ml/min.<br />After reconstitution, the solution is clear, colourless, free from foreign particles and has a pH<br />of 6.7 to 7.3.<br />For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or to mouse or
hamster proteins.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity<br />Allergic type hypersensitivity reactions, including anaphylaxis, have been reported with ADVATE. The<br />product contains traces of mouse and hamster proteins. If symptoms of hypersensitivity occur, patients<br />should be advised to discontinue use of the product immediately and contact their physician. Patients<br />should be informed of the early signs of hypersensitivity reactions including hives, generalised<br />urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.<br />In case of shock, standard medical treatment for shock should be implemented.<br />Inhibitors<br />The formation of neutralising antibodies (inhibitors) against factor VIII is a known complication in the<br />management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins<br />directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU)<br />per ml of plasma using the modified assay. In patients who develop inhibitors to factor VIII, the<br />condition may manifest itself as an insufficient clinical response. In such cases, it is recommended that<br />a specialised haemophilia centre be contacted. The risk of developing inhibitors is correlated to the<br />extent of exposure to factor VIII, the risk being highest within the first 20 exposure days, and to other<br />genetic and environmental factors. Rarely, inhibitors may develop after the first 100 exposure days.<br />Cases of recurrent inhibitor (low titre) have been observed after switching from one factor VIII<br />product to another in previously treated patients with more than 100 exposure days who have a<br />previous history of inhibitor development. Therefore, it is recommended to monitor all patients<br />carefully for inhibitor occurrence following any product switch.<br />In general, all patients treated with coagulation factor VIII should be carefully monitored for the<br />development of inhibitors by appropriate clinical observations and laboratory tests. If the expected<br />factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate<br />dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of<br />inhibitor, factor VIII substitution therapy may not be effective and other therapeutic options should be<br />considered. The management of such patients should be directed by physicians with experience in the<br />care of patients with haemophilia and factor VIII inhibitors.<br />5<br />Catheter-related complications in treatment<br />If central venous access device (CVAD) is required, risk of CVAD-related complications including<br />local infections, bacteremia and catheter site thrombosis should be considered.<br />Excipient related considerations<br />After reconstitution this medicinal product contains 0.45 mmol sodium (10 mg) per vial. To be taken<br />into consideration by patients on a controlled sodium diet.<br />It is strongly recommended that every time ADVATE is administered to a patient, the name and batch<br />number of the product are recorded in order to maintain a link between the patient and the batch of<br />the medicinal product.<br />Paediatric population:<br />The listed warnings and precautions apply to both adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with ADVATE.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal reproduction studies have not been conducted with factor VIII. Based on the rare occurrence<br />of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and<br />breast-feeding is not available. Therefore, factor VIII should be used during pregnancy and breastfeeding<br />only if clearly indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ADVATE has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Clinical studies with ADVATE included 418 subjects with at least one exposure to ADVATE reporting<br />in total 93 adverse drug reactions (ADRs). The ADRs that occurred in the highest frequency were<br />development of neutralising antibodies to factor VIII (inhibitors), headache and fever.<br />Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the<br />infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea,<br />restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed<br />rarely and may in some cases progress to severe anaphylaxis (including shock).<br />Development of antibodies to mouse and/or hamster protein with related hypersensitivity reactions<br />may be observed.<br />Patients with haemophilia A may develop neutralising antibodies (inhibitors) to factor VIII. If such<br />inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases,<br />it is recommended that a specialised haemophilia centre be contacted.<br />Tabulated summary of adverse reactions<br />The following table 2 provides the frequency of adverse drug reactions in clinical trials and from<br />spontaneous reporting. The table is according to the MedDRA system organ classification (SOC and<br />Preferred Term Level).<br />6<br />Frequency categories are defined according to the following convention: very common (&ge; 1/10),<br />common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1,000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1,000), very<br />rare (&lt; 1/10,000), not known (cannot be estimated from the available data). Within each frequency<br />grouping, undesirable effects are presented in order of decreasing seriousness.<br />Table 2 Frequency of adverse drug reactions (ADRs) in clinical trials and from spontaneous reports<br />MedDRA Standard System Organ Class Adverse reaction Frequencya<br />Infections and infestations Influenza Uncommon<br />Laryngitis Uncommon<br />Blood and lymphatic system disorders Factor VIII inhibitionc Common<br />Lymphangitis Uncommon<br />Immune system disorders Anaphylactic reaction Not known<br />Hypersensitivityc Not known<br />Nervous system disorders Headache Common<br />Dizziness Uncommon<br />Memory impairment Uncommon<br />Syncope Uncommon<br />Tremor Uncommon<br />Migraine Uncommon<br />Dysgeusia Uncommon<br />Eye disorders Eye inflammation Uncommon<br />Cardiac disorders Palpitations Uncommon<br />Vascular disorders Haematoma Uncommon<br />Hot flush Uncommon<br />Pallor Uncommon<br />Respiratory, thoracic and mediastinal disorders Dyspnoea Uncommon<br />Gastrointestinal disorders Diarrhoea Uncommon<br />Abdominal pain upper Uncommon<br />Nausea Uncommon<br />Vomiting Uncommon<br />Skin and subcutaneous tissue disorders Pruritus Uncommon<br />Rash Uncommon<br />Hyperhidrosis Uncommon<br />Urticaria Uncommon<br />General disorders and administration site<br />conditions<br />Pyrexia Common<br />Peripheral oedema Uncommon<br />Chest pain Uncommon<br />Chest discomfort Uncommon<br />Chills Uncommon<br />Feeling abnormal Uncommon<br />Vessel puncture site haematoma Uncommon<br />Fatigue Not known<br />Injection site reaction Not known<br />Malaise Not known<br />Investigations Monocyte Count increased Uncommon<br />Coagulation factor VIII level decreasedb Uncommon<br />Haematocrit decreased Uncommon<br />Laboratory test abnormal Uncommon<br />Injury, poisoning and procedural complications Post procedural complication Uncommon<br />Post procedural haemorrhage Uncommon<br />Procedural site reaction Uncommon<br />a) Calculated based on total number of patients who received ADVATE (418).<br />b) The unexpected decrease in coagulation factor VIII levels occurred in one patient during<br />continuous infusion of ADVATE following surgery (postoperative days 10-14). Haemostasis was<br />maintained at all times during this period and both plasma factor VIII levels and clearance<br />rates returned to appropriate levels by postoperative day 15. Factor VIII inhibitor assays<br />performed after completion of continuous infusion and at study termination were negative.<br />c) ADR explained in the section below.<br />7<br />Description of selected adverse reactions<br />Inhibitor Development<br />Inhibitor development in previously treated patients (PTPs) and in previously untreated patients<br />(PUPs) has been reported. For details refer to sections 5.1 (Pharmacological properties) and 4.4<br />(Special warnings and precautions for use).<br />ADRs specific to residues from the manufacturing process<br />Of the 229 treated patients who were assessed for antibodies to Chinese hamster ovary (CHO) cell<br />protein, 3 showed a statistically significant upward trend in titres, 4 displayed sustained peaks or<br />transient spikes and one patient had both but no clinical symptoms. Of the 229 treated patients who<br />were assessed for antibodies to murine IgG, 10 showed a statistically significant upward<br />trend, 2 displayed a sustained peak or transient spike and one patient had both. Four of these patients<br />reported isolated events of urticaria, pruritus, rash, and slightly elevated eosinophil counts amongst<br />repeated exposures to the study product.<br />Hypersensitivity<br />Allergic type reactions include anaphylaxis and have been manifested by dizziness, paresthesias, rash,<br />flushing, face swelling, urticaria, and pruritus.<br />Paediatric population<br />Other than the development of inhibitors in previously untreated paediatric patients (PUPs), and<br />catheter-related complications, no age-specific differences in ADRs were noted in the clinical studies.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It<br />allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare<br />professionals are asked to report any suspected adverse reactions via the national reporting system<br />listed below.<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />&bull; Toll free phone: 8002490000<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No symptoms of overdose with recombinant coagulation factor VIII have been reported.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antihaemorrhagics, blood coagulation factor VIII. ATC code: B02BD02.<br />The factor VIII/von Willebrand Factor complex consists of two molecules (factor VIII and von<br />Willebrand Factor) with different physiological functions. ADVATE contains recombinant coagulation<br />factor VIII (octocog alfa), a glycoprotein that is biologically equivalent to the factor VIII glycoprotein<br />found in human plasma.<br />Octocog alfa is a glycoprotein consisting of 2332 amino acids with an approximate molecular mass<br />of 280 kD. When infused into a haemophilia patient, octocog alfa binds to endogenous von Willebrand<br />Factor in the patient&rsquo;s circulation. Activated factor VIII acts as a Cofactor for activated Factor IX,<br />accelerating the conversion of Factor X to activated Factor X. Activated Factor X converts<br />prothrombin to thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed.<br />Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of<br />factor VIII activity and results in profuse bleeding into joints, muscles or internal organs, either<br />spontaneously or as a result of accidental or surgical trauma. The plasma levels of factor VIII are<br />increased by replacement therapy, thereby enabling a temporary correction of the factor VIII<br />deficiency and correction of the bleeding tendency.<br />Inhibitor Development<br />The immunogenicity of ADVATE was evaluated in previously treated patients. During clinical trials<br />with ADVATE in 233 paediatric and adult patients [paediatric patients (age 0 &ndash;16 years) and adult<br />patients (age over 16 years)] diagnosed with severe haemophilia A (factor VIII &lt; 1%), with previous<br />exposure to factor VIII concentrates &ge; 150 days for adults and older children and &ge; 50 days for<br />children &lt; 6 years of age, one patient developed a low-titre inhibitor (2.4 BU in the modified Bethesda<br />assay) after 26 exposure days to ADVATE. Follow-up inhibitor tests in this patient after withdrawal<br />from the study were negative. Across all studies, median exposure to ADVATE was 97.0 exposure days<br />per subject (range 1 to 709) for previously treated patients. The overall incidence of any factor VIII<br />inhibitor development (low or high) was 0.4% (1 of 233).<br />In the completed uncontrolled study 060103, 16 out of 45 (35.6%) of previously untreated patients<br />with severe haemophilia A (FVIII &lt; 1%) and at least 25 EDs to FVIII developed FVIII inhibitors: 7<br />(15.6%) subjects developed high-titre inhibitors and 9 (20%) subjects developed low-titre inhibitors, 1<br />of which was also classified as a transient inhibitor.<br />Risk factors related to inhibitor development in this study included non-Caucasian ethnicity, family<br />history of inhibitors and intensive treatment at high dose within the first 20 EDs. In the 20 subjects<br />who had none of these risk factors there was no inhibitor development.<br />Data on Immune Tolerance Induction (ITI) in patients with inhibitors have been collected. Within a<br />sub-study of PUP-study 060103, ITI-treatments in 11 PUPs were documented. Retrospective chart<br />review was done for 30 subjects on ITI (study 060703) and collection of Registry data is on-going.<br />In study 060201 two long-term prophylaxis treatment schemes have been compared in 53 PTPs: an<br />individualized pharmacokinetic guided dosing regimen (within a range of 20 to 80 IU of factor VIII<br />per kg body weight at intervals of 72 &plusmn; 6 hours, n=23) with a standard prophylactic dosing regimen<br />(20 to 40 IU/kg every 48 &plusmn;6 hours, n=30). The pharmacokinetic guided dosing regimen (according to<br />a specific formula) was targeted to maintain factor VIII trough levels &ge; 1% at the inter-dosing interval<br />of 72 hours. The data from this study demonstrate that the two prophylactic dosing regimens are<br />comparable in terms of reduction of bleeding rate.<br />The European Medicines Agency has waived the obligation to submit the results of studies with<br />ADVATE in all subsets of the paediatric population in haemophilia A (congenital factor VIII<br />deficiency) in &quot;Immune Tolerance Induction (ITI) in patients with haemophilia A (congenital factor<br />9<br />VIII deficiency) who have developed inhibitors to factor VIII&quot; and &quot;treatment and prophylaxis of<br />bleeding in patients with haemophilia A (congenital factor VIII deficiency)&quot;. (see section 4.2 for<br />information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All pharmacokinetic studies with ADVATE were conducted in previously treated patients with severe<br />to moderately severe haemophilia A (baseline factor VIII &le; 2%). The analysis of plasma samples was<br />conducted in a central laboratory using a one-stage clotting assay.<br />A total of 195 subjects with severe haemophilia A (baseline factor VIII &lt; 1%) provided PK parameters<br />that were included in the Per-Protocol PK analysis set. Categories of these analyses for infants (1<br />month to &lt;2 years of age), children (2 to &lt;5 years of age), older children (5 to &lt;12 years of age),<br />adolescents (12 to &lt;18 years of age), and adults (18 years of age and older) were used to summarize<br />PK parameters, where age was defined as age at time of PK infusion.<br />Table 3 Summary of Pharmacokinetic Parameters of ADVATE per Age Group with severe haemophilia A<br />(baseline factor VIII &lt; 1%)<br />Parameter (mean &plusmn;<br />standard deviation)<br />Infants<br />(n=5)<br />Children<br />(n=30)<br />Older Children<br />(n=18)<br />Adolescents<br />(n=33)<br />Adults<br />(n=109)<br />Total AUC (IU*&middot;h/dl) 1362.1 &plusmn;<br />311.8<br />1180.0 &plusmn;<br />432.7<br />1506.6 &plusmn; 530.0 1317.1 &plusmn;<br />438.6<br />1538.5 &plusmn; 519.1<br />Adjusted Incremental<br />Recovery at Cmax<br />(IU/dL per IU/kg)a<br />2.2 &plusmn; 0.6 1.8 &plusmn; 0.4 2.0 &plusmn; 0.5 2.1 &plusmn; 0.6 2.2 &plusmn; 0.6<br />Half-life (h) 9.0 &plusmn; 1.5 9.6 &plusmn; 1.7 11.8 &plusmn; 3.8 12.1 &plusmn; 3.2 12.9 &plusmn; 4.3<br />Maximum Plasma<br />Concentration Post<br />Infusion (IU/dl)<br />110.5 &plusmn;<br />30.2<br />90.8 &plusmn; 19.1 100.5 &plusmn; 25.6 107.6 &plusmn; 27.6 111.3 &plusmn; 27.1<br />Mean Residence<br />Time (h)<br />11.0 &plusmn; 2.8 12.0 &plusmn; 2.7 15.1 &plusmn; 4.7 15.0 &plusmn; 5.0 16.2 &plusmn; 6.1<br />Volume of<br />Distribution at<br />Steady State (dl/kg)<br />0.4 &plusmn; 0.1 0.5 &plusmn; 0.1 0.5 &plusmn; 0.2 0.6 &plusmn; 0.2 0.5 &plusmn; 0.2<br />Clearance (ml/kg*h) 3.9 &plusmn; 0.9 4.8 &plusmn; 1.5 3.8 &plusmn; 1.5 4.1 &plusmn; 1.0 3.6 &plusmn; 1.2<br />a Calculated as (Cmax - baseline Factor VIII) divided by the dose in IU/kg, where Cmax is the maximal postinfusion<br />Factor VIII measurement.<br />The safety and haemostatic efficacy of ADVATE in the paediatric population are similar to that of<br />adult patients. Adjusted recovery and terminal half-life (t&frac12;) was approximately 20% lower in young<br />children (less than 6 years of age) than in adults, which may be due in part to the known higher<br />plasma volume per kilogram body weight in younger patients.<br />Pharmacokinetic data with ADVATE on previously untreated patients are currently not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, acute<br />toxicology, repeated dose toxicity, local toxicity and genotoxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder<br />Mannitol<br />Sodium chloride<br />Histidine<br />10<br />Trehalose<br />Calcium chloride<br />Trometamol<br />Polysorbate 80<br />Glutathione (reduced)<br />Solvent<br />Sterilised water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal<br />products or solvents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
After reconstitution, from a microbiological point of view, the product should be used immediately.
However, chemical and physical in-use stability has been demonstrated for 3 hours at 25 °C.
During the shelf life, the product may be kept at room temperature (up to 25 °C) for a single period
not exceeding 6 months. The end of the 6 months storage at room temperature should be recorded on
the product carton. The product may not be returned to refrigerated storage again.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2 &deg;C &ndash; 8 &deg;C).<br />Do not freeze.<br />ADVATE with BAXJECT II device: Keep the product vial in the outer carton in order to protect from<br />light.<br />For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Both the powder vial and the vial containing 5 ml solvent are of type I glass closed with chlorobutyl<br />rubber stoppers. The product is provided in one of the following configurations:<br />- ADVATE with BAXJECT II device: Each pack contains a powder vial, a vial containing 5 ml<br />solvent and a device for reconstitution (BAXJECT II).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ADVATE is to be administered intravenously after reconstitution of the product.<br />The reconstituted solution should be inspected visually for any foreign particulate matter and/or<br />discoloration.<br />After reconstitution the solution should be clear, colourless and free from foreign particles.<br />Do not use solutions that are cloudy or have deposits.<br />- For administration the use of a luer-lock syringe is required.<br />- Use within three hours after reconstitution.<br />- Do not refrigerate the preparation after reconstitution.<br />- Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.<br />11<br />Reconstitution with the BAXJECT II device<br />- For reconstitution use only the sterilised water for injections and the reconstitution device<br />provided in the pack.<br />- Do not use if the BAXJECT II device, its sterile barrier system or its packaging is damaged or<br />shows any sign of deterioration.<br />- Aseptic Technique should be used<br />1. If the product is still stored in a refrigerator, take both the ADVATE powder and solvent vials<br />from the refrigerator and let them reach room temperature (between 15 &deg;C and 25 &deg;C).<br />2. Wash your hands thoroughly using soap and warm water.<br />3. Remove caps from powder and solvent vials.<br />4. Cleanse stoppers with alcohol swabs. Place the vials on a flat clean surface.<br />5. Open the package of BAXJECT II device by peeling away the paper lid without touching the<br />inside (Fig. a). Do not remove the device from the package. Do not use if the BAXJECT II<br />device, its sterile barrier system or its packaging is damaged or shows any sign of deterioration.<br />6. Turn the package over and insert the clear plastic spike through the solvent stopper. Grip the<br />package at its edge and pull the package off BAXJECT II (Fig. b). Do not remove the blue cap<br />from the BAXJECT II device.<br />7. For reconstitution only the sterilised water for injections and the reconstitution device provided<br />in the pack should be used. With BAXJECT II attached to the solvent vial, invert the system so<br />that the solvent vial is on top of the device. Insert the white plastic spike through the ADVATE<br />powder stopper. The vacuum will draw the solvent into the ADVATE powder vial (Fig. c).<br />8. Swirl gently until all material is dissolved. Be sure that the ADVATE powder is completely<br />dissolved, otherwise not all reconstituted solution will pass through the device filter. The<br />product dissolves rapidly (usually in less than 1 minute). After reconstitution the solution should<br />be clear, colourless and free from foreign particles.<br />Administration<br />Use Aseptic Technique<br />Parenteral medicinal products should be inspected for particulate matter prior to administration,<br />whenever solution and container permit. Only a clear and colourless solution should be used.<br />1. Remove the blue cap from BAXJECT II / BAXJECT III. Do not draw air into the syringe.<br />Connect the syringe to BAXJECT II / BAXJECT III.<br />2. Invert the system (the vial with the reconstituted solution has to be on top). Draw the<br />reconstituted solution into the syringe by pulling the plunger back slowly.<br />3. Disconnect the syringe.<br />4. Attach a butterfly needle to the syringe. Inject intravenously. The solution should be<br />administered slowly, at a rate as determined by the patient&rsquo;s comfort level, not to exceed 10 ml<br />per minute. The pulse rate should be determined before and during administration of ADVATE.<br />Should a significant increase occur, reducing the rate of administration or temporarily<br />interrupting the injection usually allows the symptoms to disappear promptly (see<br />sections 4.4 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Takeda Manufacturing Austria AG
Industriestrasse 67
1221
Austria
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                25-10-2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>